{"drugs":["Amifostine","Ethyol"],"mono":{"0":{"id":"923557-s-0","title":"Generic Names","mono":"Amifostine"},"1":{"id":"923557-s-1","title":"Dosing and Indications","sub":{"0":{"id":"923557-s-1-4","title":"Adult Dosing","mono":"<ul><li>prior to therapy, patient should be adequately hydrated and normotensive<\/li><li><b>Cisplatin nephropathy; Prophylaxis - Ovarian cancer, Advanced:<\/b> 910 mg\/m(2) IV over 15 minutes daily, given 30 minutes before chemotherapy; premedicate with dexamethasone 20 mg IV and 5HT3 antagonist before and during therapy; antihypertensive therapy should be interrupted 24 hours prior to  administration of amifostine; patients should not receive  amifostine if antihypertensive therapy cannot be stopped.<\/li><li><b>Cisplatin nephropathy; Prophylaxis - Ovarian cancer, Advanced:<\/b> monitor blood pressure every 5 minutes during therapy and thereafter as necessary; interrupt therapy if the systolic blood pressure decreases significantly from baseline (baseline value, decrease) as follows: less than 100, 20; 100 to 119, 25; 120 to 139, 30; 140 to 179, 40; greater than or equal to 180, 50; if the patient is asymptomatic and returns to normal within 5 minutes, restart the infusion so that the full dose may be given; if the full dose cannot be given, dose at 740 mg\/m(2) for subsequent chemotherapy cycles<\/li><li><b>Radiation-induced xerostomia (Moderate to Severe), Post-operative in head and neck cancers; Prophylaxis:<\/b> 200 mg\/m(2)\/day IV over 3 minutes, 15 to 30 minutes before standard fraction radiation (1.8 to 2 Gray); monitor blood pressure before and immediately after infusion and as clinically indicated; adequately hydrate patients prior to administration, antiemetics (ie, 5HT3 antagonists, alone or in combination with other antiemetics) should be administered prior to and in conjunction with the infusion<\/li><\/ul>"},"1":{"id":"923557-s-1-5","title":"Pediatric Dosing","mono":"safety and effectiveness not established in children "},"3":{"id":"923557-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Cisplatin nephropathy; Prophylaxis - Ovarian cancer, Advanced<\/li><li>Radiation-induced xerostomia (Moderate to Severe), Post-operative in head and neck cancers; Prophylaxis<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Adverse effect of radiation therapy, Radioiodine - Disturbance of salivary secretion<\/li><li>Antineoplastic adverse reaction - Myelosuppression<\/li><li>Antineoplastic adverse reaction - Nephrotoxicity<\/li><li>Malignant melanoma; Adjunct<\/li><li>Myelodysplastic syndrome<\/li><li>Myelosuppression - Radiation-induced disorder<\/li><li>Non-small cell lung cancer; Adjunct<\/li><li>Radiation proctitis<\/li><li>Radiation respiratory disease<\/li><\/ul>"}}},"3":{"id":"923557-s-3","title":"Contraindications\/Warnings","sub":[{"id":"923557-s-3-9","title":"Contraindications","mono":"hypersensitivity to aminothiol compounds <br\/>"},{"id":"923557-s-3-10","title":"Precautions","mono":"<ul><li>allergic manifestations, including anaphylaxis, have been reported<\/li><li>antitumor efficacy may be reduced when amifostine is administered prior to cisplatin therapy in settings other than advanced ovarian cancer<\/li><li>cardiovascular\/cerebrovascular conditions (eg, ischemic heart disease, arrhythmias, congestive heart failure, or history of stroke or ischemic attacks), preexisting; hypotensive adverse effect may have serious consequences<\/li><li>concomitant therapy with antihypertensive medications or drugs that could cause or potentiate hypotension; hypotensive adverse effect may have serious consequences<\/li><li>concomitant antihypertensive agents that cannot be interrupted 24 hours before amifostine; amifostine use not recommended<\/li><li>definitive radiotherapy; use not recommended<\/li><li>cutaneous reactions, serious (eg, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis) and some fatal have been reported; monitoring is recommended<\/li><li>dehydration; use not recommended<\/li><li>fluid imbalance due to nausea and vomiting; monitoring recommended<\/li><li>hypocalcemia; monitoring is recommended in patients at risk (ie, nephrotic syndrome, receiving multiple doses of amifostine)<\/li><li>hypotension, preexisting; use not recommended<\/li><li>hypotension, associated with dyspnea, apnea, hypoxia and rarely with seizures, unconsciousness, respiratory arrest and renal failure has occurred during or shortly after amifostine administration; monitoring is recommended<\/li><\/ul>"},{"id":"923557-s-3-11","title":"Pregnancy Category","mono":"<ul><li>C (FDA)<\/li><li>B3 (AUS)<\/li><\/ul>"},{"id":"923557-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"923557-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Hypotension (ovarian cancer, 61%; head and neck cancer, 15%)<\/li><li><b>Gastrointestinal:<\/b>Diarrhea, Nausea and vomiting (53% to 96%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Dermatologic:<\/b>Erythema multiforme, Erythroderma, Stevens-Johnson syndrome, Toxic epidermal necrolysis<\/li><li><b>Immunologic:<\/b>Anaphylactoid reaction, Hypersensitivity reaction<\/li><li><b>Neurologic:<\/b>Loss of consciousness<\/li><\/ul>"},"6":{"id":"923557-s-6","title":"Drug Name Info","sub":{"0":{"id":"923557-s-6-17","title":"US Trade Names","mono":"Ethyol<br\/>"},"2":{"id":"923557-s-6-19","title":"Class","mono":"Cytoprotective Agent<br\/>"},"3":{"id":"923557-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"923557-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"923557-s-7","title":"Mechanism Of Action","mono":"Systemic: Amifostine is a prodrug that is metabolized by alkaline phosphatase to an active free thiol metabolite.   The active thiol metabolite reduces cytotoxicity by binding to and detoxifying reactive metabolites of cisplatin   and alkylating agents   and by acting as a scavenger of free radicals   that may develop in tissues exposed to cisplatin or radiation. These actions occur more readily in normal tissue than in tumors because of the greater phosphatase activity, higher pH, and better vascularity in normal tissue , resulting in selective protection of normal tissues .<br\/>"},"8":{"id":"923557-s-8","title":"Pharmacokinetics","sub":{"2":{"id":"923557-s-8-25","title":"Metabolism","mono":"Systemic: Active metabolites: thiol metabolite and disulfide metabolite<br\/>"},"3":{"id":"923557-s-8-26","title":"Excretion","mono":"<ul><li>Systemic: Amifostine- Renal: 0.69%<\/li><li>Disulfide metabolite- Renal: 2.22%<\/li><li>Thiol metabolite- Renal: 2.64% <\/li><\/ul>"},"4":{"id":"923557-s-8-27","title":"Elimination Half Life","mono":"Systemic: 8 min <br\/>"}}},"9":{"id":"923557-s-9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>reconstitute amifostine powder with 9.7 mL sterile NS 0.9% to provide a concentration of 500 mg\/10 mL (single-use vial) or concentrations ranging from 5 mg\/mL to 40 mg\/mL (polyvinylchloride bags); administer within 5 hours if stored at room temperature and within 24 hours if stored under refrigeration<\/li><li>administer infusion to patient in supine position over 15 minutes starting 30 minutes prior to chemotherapy when used for the reduction of cumulative renal toxicity with chemotherapy; administer infusion over 3 minutes starting 15 to 30 minutes before standard fraction radiation therapy when use for reduction of moderate to severe xerostomia from radiation of the head and neck<\/li><li>interrupt therapy if systolic blood pressure decreases significantly from baseline (baseline value, decrease): less than 100, 20; 100 to 119, 25; 120 to 139, 30; 140 to 179, 40; greater than or equal to 180, 50; if patient is asymptomatic and returns to normal within 5 minutes, restart infusion so that full dose may be given; if full dose cannot be given, dose at 740 mg\/m(2) for subsequent chemotherapy cycles<\/li><\/ul>"},"10":{"id":"923557-s-10","title":"Monitoring","mono":"<ul><li>normal renal function is indicative of efficacy in patients with advanced ovarian cancer<\/li><li>reduction in symptoms of xerostomia in patients undergoing radiation for head and neck cancer is indicative of efficacy<\/li><li>blood pressure; prior to therapy initiation, at 5 minute intervals during long infusions, immediately after infusions lasting less than 5 minutes, and as clinically indicated; closely monitor patients whose antihypertensive treatment was interrupted for amifostine therapy<\/li><li>cutaneous reactions (rash involving lips, erythematous, edematous, or bullous lesions of palms of hands or soles of feet, trunk involvement, cutaneous reaction associated with fever or other constitutional symptoms, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, toxoderma, and exfoliative dermatitis); monitor prior to, during, immediately after, and weeks following amifostine therapy, especially when used as a chemoprotectant; requires permanent discontinuation of therapy if serious or severe cutaneous reactions or mucosal lesions do not have other etiologies, or occur outside the injection site or radiation port, or include erythematous, edematous, or bullous lesions of palms of hands or soles of feet<\/li><li>hypersensitivity reactions including anaphylaxis may occur<\/li><li>fluid balance; when coadministered with highly emetogenic chemotherapy<\/li><li>serum calcium in patients at risk of hypocalcemia (eg, nephrotic syndrome, multiple amifostine doses)<\/li><\/ul>"},"11":{"id":"923557-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/>Intravenous Powder for Solution: 500 MG<br\/><\/li><li><b>Ethyol<\/b><br\/>Intravenous Powder for Solution: 500 MG<br\/><\/li><\/ul>"},"12":{"id":"923557-s-12","title":"Toxicology","sub":[{"id":"923557-s-12-31","title":"Clinical Effects","mono":"<b>AMIFOSTINE<\/b><br\/>OVERDOSE: No human data.  ADVERSE EFFECTS: Hypotension, transient loss of consciousness; nausea, vomiting, and hypocalcemia. <br\/>"},{"id":"923557-s-12-32","title":"Treatment","mono":"<b>AMIFOSTINE<\/b><br\/><ul><li>Decontamination: Not indicated; IV medication.<\/li><li>Hypotensive episode: IV 0.9% NaCl 10-20 ml\/kg, dopamine, norepinephrine.<\/li><li>Hypocalcemia: IV calcium chloride or calcium gluconate<\/li><li>Vomiting: May require aggressive use of antiemetic.  IV decadron 20 mg and ondansetron 8 mg. Alternatives include metoclopromide and droperidol<\/li><li>Monitoring of patient: Monitor BP frequently, ECG and continuous cardiac monitoring.  Fluid and electrolyte status with significant vomiting. Monitor calcium.<\/li><\/ul>"},{"id":"923557-s-12-33","title":"Range of Toxicity","mono":"<b>AMIFOSTINE<\/b><br\/>Unknown. Usual Adult dose: 910 mg\/m2; Children: single doses up to 2700 mg\/m2 have been used in clinical trials. <br\/>"}]},"13":{"id":"923557-s-13","title":"Clinical Teaching","mono":"<ul><li>This drug may cause diarrhea, nausea, vomiting, somnolence, sneezing, or hiccoughs.<\/li><li>Advise patient to report signs\/symptoms of a severe skin reaction such as Stevens-Johnson syndrome (flu-like symptoms, spreading red rash, or skin\/mucous membrane blistering), erythema multiforme (a less severe form of Stevens-Johnson), erythroderma (reddened skin, skin peeling\/flaking), or toxic epidermal necrolysis (widespread peeling\/blistering of skin).<\/li><li>Instruct patient to report signs\/symptoms of hypotension.<\/li><li>Advise patient to stay supine during infusion. Blood pressure will be monitored frequently.<\/li><li>Instruct patient to drink plenty of fluids 24 h before dose.<\/li><\/ul>"}}}